Thursday 14th September 2023 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has exported to Australia its first commercial shipment of its high-purity cannabidiol (CBD) isolate, a cannabis-based, active pharmaceutical ingredient (API). This is a first for Aotearoa New Zealand’s medicinal cannabis industry.
This CBD isolate was manufactured in New Zealand to PIC/s Good Manufacturing Practice (GMP) standards and verified by the Medicinal Cannabis Agency. This first shipment is the forerunner of greater volumes of API exports for the local industry, signalling the demand for high-quality, GMP certified cannabis-based APIs on the international stage.
This signals the next growth phase for Cannasouth and the medicinal cannabis industry.
-ENDS-
No comments yet
AIA - Auckland Airport considers bond offers
September 22nd Morning Report
September 19th Morning Report
Smartpay Scheme Booklet and Notice of Meeting
September 18th Morning Report
Seeka Increases Forecast Full Year Earnings Guidance
TEM - Ability to invest in derivatives
Devon Funds Morning Note - 16 September 2025
September 17th Morning Report
MPG - Recapitalisation Closes Oversubscribed, Raises $23.9m